Physician profile
Piotr P Witkowski
NPI 1104058023
$234,898.70
in general payments reported to CMS, 2019-2025
11 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,375 · 2020: $37K · 2021: $18K · 2022: $43K · 2023: $13K · 2024: $47K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $107K · Travel and Lodging: $24K · Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $107,167.75 |
| Travel and Lodging | $23,759.44 |
| Food and Beverage | $957.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $176,874.91 | 2019-2025 | |
| Novo Nordisk As | $24,892.67 | 2025 | |
| Sanofi US Services INC. | $18,773.13 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $12,804.00 | 2025 | |
| Insulet Corporation | $1,050.00 | 2025 | Omnipod |
| Paragonix Technologies, INC. | $201.34 | 2024 | Baroguard, Liverguard, Lungguard |
| Veloxis Pharmaceuticals, INC. | $175.01 | 2019 | |
| Boston Scientific Corporation | $48.02 | 2024 | Ekosonic |
| Genzyme Corporation | $40.00 | 2025 | |
| Ethicon US, LLC | $39.62 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piotr Witkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.